Published financial brief
0447B
ALIGOS THERAPEUTICS INC
- As of
- 2024-12-31
- Source
- Supabase fundamentals
- Calculator
- financial-roic-1.0.0
- Published
- 7/26/2026
4 data notes
- Input provenance requires review.
- A ratio denominator is near zero.
- One or more values are unavailable.
- A displayed ratio exceeds the warning bound.
Exact-period record
Fundamentals
5 reported periods
| Metric | FY 20202020-12-31 | FY 20212021-12-31 | FY 20222022-12-31 | FY 20232023-12-31 | FY 20242024-12-31 |
|---|---|---|---|---|---|
| Financial statements | |||||
| RevenueUSD millions | 0 | 4.4 | 13.9 | 15.5 | 3.9 |
| Cost of goods soldUSD millions | 0 | 129.7 | 109.2 | 101.4 | 92.1 |
| Selling, general and administrative expenseUSD millions | 95.1 | —missing | —missing | —missing | —missing |
| Depreciation and amortizationUSD millions | 2.7 | 3 | 2.3 | 1.6 | 1 |
| Net incomeUSD millions | -108.5 | -128.3 | -96 | -87.7 | -131.2 |
| Operating profit (EBIT)USD millions | -97.8 | -128.3 | -97.6 | -87.4 | -89.2 |
| Income taxesUSD millions | 0.2 | 0.1 | 0.1 | 0.8 | 0.3 |
| Short-term debtUSD millions | 2.5 | 2.9 | 3.1 | 3.2 | 3.5 |
| Long-term debtUSD millions | 10.5 | 11.5 | 9.4 | 7.9 | 4.9 |
| Cash and equivalentsUSD millions | 244.1 | 190.9 | 125.9 | 135.8 | 57 |
| ReceivablesUSD millions | 0 | 0 | 0 | 0 | 0 |
| InventoryUSD millions | 0 | 0 | 0 | 0 | 0 |
| PayablesUSD millions | 3.3 | 3 | 4.7 | 2.5 | 2.6 |
| Net property, plant and equipmentUSD millions | 14.9 | 15 | 12.5 | 9.8 | 7.3 |
| Capital expenditureUSD millions | 2.1 | 0.9 | 0.9 | 0 | 0.1 |
| Operating cash flowUSD millions | -74.3 | -115.7 | -79.4 | -79 | -80.7 |
| Prepaid expensesUSD millions | 0 | 0 | 0 | 0 | 0 |
| AccrualsUSD millions | 16.6 | 25.4 | 16 | 16.8 | 15.6 |
| EBITDAUSD millions | -95.1 | -125.3 | -95.3 | -85.8 | -88.1 |
| Working capitalUSD millions | 219.7 | 165.5 | 100.4 | 117.2 | 40.4 |
| Working capital requirementUSD millions | -3.3 | -3 | -4.7 | -2.5 | -2.6 |
| Total debtUSD millions | 13 | 14.5 | 12.6 | 11.1 | 8.4 |
| Free cash flowUSD millions | -76.3 | -116.6 | -80.3 | -79 | -80.9 |
| Unlevered free cash flowUSD millions | -97.6 | -126.5 | -94.5 | -88.1 | -88.2 |
| Returns and ratios | |||||
| ROICratio | -843.8% | -1,073.5% | -1,254.7% | -1,197.1% | -1,875% |
| Pre-tax ROICratio | -843.8% | -1,073.5% | -1,254.7% | -1,197.1% | -1,875% |
| Effective tax rateratio | 0% | 0% | 0% | 0% | 0% |
| Revenue growthratio | —missing | —missing | 219% | 11.7% | -74.6% |
| EBIT / Revenueratio | —missing | -2,943.8% | -701.7% | -562.8% | -2,259.9% |
| Revenue / Invested capitalmultiple | 0× | 0.36× | 1.79× | 2.13× | 0.83× |
| Cogs Over Revenuesratio | —missing | 2,974.6% | 785.1% | 652.8% | 2,333.9% |
| Sga Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Da Over Revenuesratio | —missing | 69.3% | 16.6% | 10% | 26% |
| Nfa Over Revenuesratio | —missing | 343.4% | 90% | 63.2% | 185.7% |
| Wcr Over Revenuesratio | —missing | -69.2% | -34.1% | -16.2% | -65.2% |
| Debt Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| St Debt Over Cashmultiple | 0.01× | 0.02× | 0.02× | 0.02× | 0.06× |
| Interest Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| Interest Over Nocf Nicfmultiple | -0× | —missing | —missing | —missing | —missing |
| Nsf Over Wcrmultiple | 72.92× | 62.35× | 25.92× | 52.66× | 20.84× |
Ask this snapshot
Research assistant
0447B · annualSnapshot 196cd117
Answers use only this published snapshot. The assistant will say when the data is insufficient and does not create forecasts, scenarios, or investment advice.
0 / 2,000